The cannabis landscape has transformed dramatically over recent decades, with today’s products bearing little resemblance to those from previous generations. Modern cannabis flower typically contains more than 15% THC—the psychoactive compound delta-9-tetrahydrocannabinol—whilst concentrated products can reach a staggering 90% or higher. This surge in potency poses unprecedented challenges for young people’s mental health.

Research comparing historical samples reveals the stark reality: cannabis tested at Woodstock in 1969 contained approximately 1% THC. The dramatic increase in potency has coincided with alarming rises in cannabis-related mental health conditions, particularly amongst adolescents and emerging adults.

The Expanding Cannabis Product Market

Today’s cannabis consumers face an array of ultra-potent products that were unimaginable a generation ago. Concentrates such as wax exceed 60% THC concentration, whilst shatter—a glass-like substance that fractures when broken—can contain 90% THC. Products marketed as THC Diamonds, Dabs, Moon Rocks, Crumble, Live Resin, and Rosin represent the highest end of potency.

Vaping cartridges typically contain 50-95% THC concentration, whilst edibles range from 5-10mg per serving, though packages of 100mg are commonly sold. The most extreme product, THC isolate, is nearly pure THC in crystal or powder form, reaching concentrations exceeding 99%.

In the UK, recent data shows a troubling shift towards higher-potency products in the medical cannabis market. Products above 22% THC accounted for around one-third of all prescribed volume by 2024, and by early 2025, they comprised almost half of all prescriptions. This structural shift highlights growing demand for stronger cannabis preparations.

Adolescent Brains Under Siege

The adolescent brain remains particularly vulnerable to high-potency cannabis due to ongoing development, especially in the prefrontal cortex—the region governing decision-making, impulse control, and emotional regulation. Exposure to elevated THC levels during this critical developmental window can produce significant, lasting effects on brain structure, function, and behaviour.

Dr Yasmin Hurd, a neuroscientist at the Icahn School of Medicine, emphasises that the adolescent brain is highly vulnerable to THC due to ongoing development. Her research demonstrates that early THC exposure disrupts neural connections, leading to persistent issues with memory, learning, and emotional control.

Studies reveal multiple concerning impacts on developing brains. THC disrupts the hippocampus, a region essential for memory formation, potentially causing difficulties in learning and retaining information. Long-term cannabis use initiated during adolescence has been associated with declining IQ scores and cognitive performance.

High-THC exposure can reduce grey matter volume in the prefrontal cortex, impairing executive functions such as planning and impulse control. The substance also affects the brain’s white matter, reducing connectivity between brain regions crucial for coordinated cognitive processes.

Cannabis Psychosis Risk Surges Among Young Users

Recent UK research from the Children of the 90s study found that 10.1% of young people using higher-potency cannabis reported new psychotic experiences, compared to 3.8% using lower-potency products. Those using high-potency cannabis were more than twice as likely to report new psychotic experiences after beginning use.

A landmark investigation analysed 780 adults aged 18-65, with 410 experiencing their first psychotic episode compared to 370 matched healthy controls. The findings showed that use of high-potency THC above 15% resulted in a three times increased risk of psychosis, and daily use increased this risk fivefold.

Dr Marta Di Forti, who leads the UK’s only NHS Cannabis Clinic for Psychosis, observes that young people using cannabis harmfully often develop clinical psychosis with disabling paranoia and intrusive delusional thoughts. The clinic’s data shows that at the time of referral, 93% of participants were using high-potency cannabis, and 91% were using cannabis daily.

The CDC notes that cannabis use can increase risks for psychosis or schizophrenia, especially in men and those starting use at an early age. High-potency products contribute to an earlier onset of symptoms in users, with adolescents facing heightened risks for developing cannabis-induced psychosis and long-term psychiatric disorders such as schizophrenia, particularly those with genetic predisposition.

Mental Health and Addiction Consequences

Cannabis use disorder has become increasingly prevalent, particularly in regions with legalised recreational cannabis. Regular use of high-potency products is associated with an increased likelihood of dependence, craving, and withdrawal symptoms.

Chronic cannabis use has been linked to increased anxiety and depression, suicidal thoughts, and completed suicides in adolescents. According to available estimates, 9% of those experimenting with cannabis will become addicted, 17% of those starting as teenagers will develop addiction, and 25-50% of daily users will experience addiction.

Research shows that adolescents are more likely than adults to develop cannabis use disorder due to heightened neuroplasticity during this developmental stage, making the brain more susceptible to addiction. According to Dr Chris Hammond, a Johns Hopkins University researcher, cannabis use is associated with suicide-related outcomes in both adolescents and adults.

Cardiovascular and Cognitive Impacts

The cardiovascular effects of high-potency cannabis products include increased heart rate and blood pressure, which may exacerbate underlying heart conditions and induce heart-related emergencies. Daily consumption, particularly of inhaled or high-potency products, may contribute to cardiovascular problems, including elevated risks of coronary heart disease, heart attack, and stroke.

THC impairs motor coordination, reaction time, and judgement, increasing risks for road traffic accidents and other incidents. Higher THC doses cause more pronounced impairment, and individuals with THC in their system are more likely to cause accidents.

The Mounting Evidence

In the UK, 2.3 million people reported using cannabis in the year to March 2024. Skunk, made from unpollinated cannabis plants with naturally higher THC levels, creates stronger effects and greatly increases the likelihood of paranoia and hallucinations—both symptoms closely associated with psychotic disorders.

A recent systematic review of nearly 100 studies found strong links between high-concentration THC products and psychosis, schizophrenia, and cannabis use disorder. The review defined high-concentration cannabis as products with THC concentration exceeding 5mg THC or 10% THC per serving, or products described as “high-potency concentrate,” “shatter,” or “dab.”

Dr Nora Volkow, director of the National Institute on Drug Abuse, emphasises prevention and warns about the potential harm cannabis poses to adolescent brain development. She stresses the importance of non-use during critical developmental periods to minimise risks of marijuana-related psychosis.

Research has shown that individuals consuming high-THC cannabis daily are more prone to schizophrenia and early-onset psychosis, suggesting a dose-response relationship between THC potency and adverse mental health outcomes. As cannabis psychosis risk surges globally, experts warn that immediate action is needed to protect vulnerable populations.

The Warning Label Gap

Unlike cigarettes and alcoholic beverages, which carry standardised health warnings based on research evidence, cannabis product warnings remain inconsistent across regions. Some jurisdictions provide only basic warnings about keeping products away from children, whilst others offer limited information about health hazards, including the risk of psychosis.

Educational campaigns, evidence-based labels, and restrictions on sales and marketing could help mitigate risks. Experts increasingly advocate for federal measures to reduce harms associated with ultra-high-THC cannabis products and to better inform consumers about cannabis-related psychotic disorders.

Long-Term Consequences for Young People

Some neurobiological effects of adolescent cannabis use, such as reduced grey matter volume and altered connectivity, may persist into adulthood, even after substance use stops. The resulting impaired cognitive and emotional regulation may lead to academic underperformance and difficulties in interpersonal relationships.

Rapid shifts in cannabis policies and the commercialisation of cannabis carry unknown health implications for young people. With cannabis psychosis risk surging in communities where high-potency products are readily available, public health officials face mounting pressure to implement protective measures.

Looking Forward

Neuroscience research has advanced understanding of cannabis pharmacology and the endocannabinoid system. Rising THC potency correlates with increased risks of cannabis use disorder, cardiovascular issues, psychosis, accidents, depression, and impaired driving.

Specialists warn that cannabis should not be used by pregnant women, children, teenagers, or young adults. Cannabis use by teens and young adults is causing increasing rates of schizophrenia, psychosis, depression, and suicide.

Whilst cannabis research has identified therapeutic possibilities for pain or sleep medicines and may lead to treatments that prevent cannabis toxicity, the evidence strongly suggests that protecting young people from high-potency cannabis products must remain a priority for public health policy.

Understanding the link between potent cannabis and psychotic disorders is crucial for developing effective prevention strategies and ensuring young people are fully informed about the serious mental health consequences of using today’s ultra-strong cannabis products.

Source: PsychologyToday